Read by QxMD icon Read

Lupus Science & Medicine

Maarten Boers
No abstract text is available yet for this article.
2017: Lupus Science & Medicine
Line Kjær Winberg, Claus Henrik Nielsen, Søren Jacobsen
OBJECTIVES: To examine microparticles (MPs) from patients with SLE and healthy controls (HCs) by determining the cellular origin of the MPs, quantifying attached fragments of complement component 3 (C3) and assessing the ability of MPs to bind to circulating phagocytes and erythrocytes. These features may be relevant for clearance of MPs in SLE pathogenesis. METHODS: Attached C3 fragments (C3b, iC3b, C3d), membrane integrity and cell surface markers of MPs from 18 patients with SLE and 11 HCs were measured by adding specific antibodies, 7-aminoactinomycin D (7AAD) and annexin V...
2017: Lupus Science & Medicine
Teresa Aberle, Rebecka L Bourn, Hua Chen, Virginia C Roberts, Joel M Guthridge, Krista Bean, Julie M Robertson, Kathy L Sivils, Astrid Rasmussen, Meghan Liles, Joan T Merrill, John B Harley, Nancy J Olsen, David R Karp, Judith A James
OBJECTIVE: SLE is traditionally classified using the American College of Rheumatology (ACR) criteria. The Systemic Lupus International Collaborating Clinics (SLICC) recently validated an alternative system. This study examined large cohorts of subjects with SLE and incomplete lupus erythematosus (ILE) to compare the impact of ACR and SLICC criteria. METHODS: Medical records of subjects in the Lupus Family Registry and Repository were reviewed for documentation of 1997 ACR classification criteria, SLICC classification criteria and medication usage...
2017: Lupus Science & Medicine
Sarika M Ramachandran, Jonathan S Leventhal, Loren G Franco, Adnan Mir, Ruth F Walters, Andrew G Franks
Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histological features. Drug-induced SCLE has been reported with various oral agents, but to our knowledge this is the first reported case due to a topical medication...
2017: Lupus Science & Medicine
Noémi Györi, Ioanna Giannakou, Katerina Chatzidionysiou, Laurence Magder, Ronald F van Vollenhoven, Michelle Petri
OBJECTIVE: To describe SLE disease activity patterns in the Hopkins Lupus Cohort. METHODS: Disease activity was studied in 1886 patients followed-up for 1-28 years. Disease activity patterns were defined using (1) Physician Global Assessment (PGA) and (2) modified SLE Disease Activity Index (M-SLEDAI) as follows: long quiescent (LQ), M-SLEDAI=0/PGA=0 at all visits; relapsing-remitting (RR), periods of activity (M-SLEDAI>0/PGA>0) interspersed with inactivity (M-SLEDAI=0/PGA=0); chronic active (CA), M-SLEDAI>0/PGA>0 at all visits...
2017: Lupus Science & Medicine
Patricia P Katz, James Andrews, Jinoos Yazdany, Gabriela Schmajuk, Laura Trupin, Edward Yelin
OBJECTIVE: In geriatric populations, frailty is associated with poor health outcomes, including mortality. Frailty has not been examined in lupus, although components of the phenotype seem relevant. METHODS: Women with lupus (n=152) participated in research visits in 2008-2009. Frailty was assessed by Fried's frailty phenotype criteria: low weight/unintentional weight loss, slow gait (4-m walk using sex and height criteria), weakness (grip strength using gender and body mass index criteria), exhaustion (2 specific questions) and inactivity (from physical activity questionnaire)...
2017: Lupus Science & Medicine
Borja Gracia-Tello, Amara Ezeonyeji, David Isenberg
BACKGROUND: Previous reports indicate that treating patients with lupus (SLE) at or close to the time of diagnosis successfully without using any, or minimal, corticosteroids by using B-cell depletion (BCD) is possible in the short-term. It is not however known whether using BCD is as effective or reduces corticosteroid use in the long-term. We report the long-term (up to 7 years) use of BCD with respect to its steroid-saving capacity and clinical effectiveness in newly diagnosed SLE...
2017: Lupus Science & Medicine
Alison L Nightingale, Julie E Davidson, Charles T Molta, Hong J Kan, Neil J McHugh
OBJECTIVES: To describe the presenting symptoms of SLE in primary care using the Clinical Practice Research Database (CPRD) and to calculate the time from symptom presentation to SLE diagnosis. METHODS: Incident cases of SLE were identified from the CPRD between 2000 and 2012. Presenting symptoms were identified from the medical records of cases in the 5 years before diagnosis and grouped using the British Isles Lupus Activity Group (BILAG) symptom domains. The time from the accumulation of one, two and three BILAG domains to SLE diagnosis was investigated, stratified by age at diagnosis (<30, 30-49 and ≥50 years)...
2017: Lupus Science & Medicine
Jose-Gabriel Erdozain, Irama Villar, Javier Nieto, Ioana Ruiz-Arruza, Guillermo Ruiz-Irastorza
OBJECTIVE: To analyse the differential influence of risk factors of peripheral artery disease (PAD) according to age in patients with SLE. METHODS: 216 patients from the Lupus-Cruces cohort were divided in three age groups: ≤34 years, 35-49 years and ≥50 years. A low ankle-brachial index defined PAD. Significant variables were identified by univariant and multivariant analysis in each age group. RESULTS: Different factors were identified in different age groups: antiphospholipid antibodies/antiphospholipid syndrome and glucocorticoids in patients ≤34 years; in patients 35-49 years old, hypertension was the only statistically significant predictor, although a trend was observed for fibrinogen levels; a trend was observed for hypercholesterolaemia in those ≥50 years...
2017: Lupus Science & Medicine
Carina A Ruano, Rui Malheiro, João F Oliveira, Sofia Pinheiro, Luís S Vieira, Maria Francisca Moraes-Fontes
OBJECTIVES: To assess the prevalence and severity of ultrasonographic abnormalities of the hand and wrist of asymptomatic patients with systemic lupus erythematosus (SLE) and compare these findings with those from patients with SLE with musculoskeletal signs or symptoms and healthy controls. METHODS: We conducted a prospective cross-sectional study that evaluated bilaterally, with grey-scale and power Doppler (PD) ultrasound (US), the dorsal hand (2nd to 5th metacarpophalangeal and 2nd to 5th proximal interphalangeal joints) and wrist (radiocarpal, ulnocarpal and intercarpal joints) of 30 asymptomatic patients with SLE, 6 symptomatic patients with SLE and 10 controls...
2017: Lupus Science & Medicine
Peter Korsten, Daniel Patschan, Elvira Henze, Timothy B Niewold, Gerhard Anton Müller, Susann Patschan
Patients with SLE display a significantly higher cardiovascular risk (CVR). Pulse wave velocity (PWV) has meanwhile been established as a reliable parameter of end-organ damage. Endothelial progenitor cells (EPCs) are critically involved in vascular repair under both physiological and pathological conditions. The aim of the study was to analyse PWV and the Vascular Augmentation Index (VAI) and EPC numbers/regeneration in a well-defined German SLE cohort. Thirty patients were included. Only two individuals displayed a PWV of above 10 m/s...
2016: Lupus Science & Medicine
Tineke Kraaij, Obbo W Bredewold, Stella Trompet, Tom W J Huizinga, Ton J Rabelink, Anton J M de Craen, Y K Onno Teng
Current guidelines do not mention tacrolimus (TAC) as a treatment option and no consensus has been reported on the role of TAC in lupus nephritis (LN). The present study aimed to guide clinical judgement on the use of TAC in patients with LN. A meta-analysis was performed for clinical studies investigating TAC regimens in LN on the basis of treatment target (induction or maintenance), concomitant immunosuppression and quality of the data. 23 clinical studies performed in patients with LN were identified: 6 case series, 9 cohort studies, 2 case-control studies and 6 randomised controlled trials (RCTs)...
2016: Lupus Science & Medicine
Laura Geraldino-Pardilla, Yevgeniya Gartshteyn, Paloma Piña, Marina Cerrone, Jon T Giles, Afshin Zartoshti, Joan M Bathon, Anca D Askanase
OBJECTIVES: Cardiovascular disease (CVD) is a leading cause of death in systemic lupus erythematosus (SLE) and in rheumatoid arthritis (RA). Although only explored in one study, ECG non-specific ST-T abnormalities, in addition to corrected QT-interval (QTc) prolongation, were recently reported in an SLE inception cohort. Importantly, these ECG abnormalities are known predictors of CVD mortality in the general population, yet their prevalence in patients with established SLE has not been evaluated...
2016: Lupus Science & Medicine
Pietro Enea Lazzerini, Pier Leopoldo Capecchi, Franco Laghi-Pasini
No abstract text is available yet for this article.
2016: Lupus Science & Medicine
Amanda Mok, Olivia Solomon, Renuka R Nayak, Patrick Coit, Hong L Quach, Joanne Nititham, Amr H Sawalha, Lisa F Barcellos, Lindsey A Criswell, Sharon A Chung
OBJECTIVE: Previous studies have shown that differential DNA methylation is associated with SLE susceptibility. How DNA methylation affects the clinical heterogeneity of SLE has not been fully defined. We conducted this study to identify differentially methylated CpG sites associated with nephritis among women with SLE. METHODS: The methylation status of 428 229 CpG sites across the genome was characterised for peripheral blood cells from 322 women of European descent with SLE, 80 of whom had lupus nephritis, using the Illumina HumanMethylation450 BeadChip...
2016: Lupus Science & Medicine
Ralph Brinks, Annika Hoyer, Sergej Weber, Rebecca Fischer-Betz, Oliver Sander, Jutta G Richter, Gamal Chehab, Matthias Schneider
OBJECTIVE: To provide an estimate of age-specific incidence rate of physician-diagnosed systemic lupus erythematosus (SLE) for German men and women. METHODS: The age-specific and sex-specific prevalence of diagnosed SLE in claims data is used to estimate the incidence in the German male and female population. The claims data set stems from a representative sample of the statutory health insurance in 2002 and comprises 2.3 million people. The statutory health insurance covers >85% of the German population...
2016: Lupus Science & Medicine
Richard Furie, Margaret Mitrane, Enxu Zhao, Maya Das, Daner Li, Patrice M Becker
OBJECTIVE: To evaluate the efficacy of a prolonged-release formulation of a porcine adrenocorticotropic hormone analogue (repository corticotropin injection (RCI)) added to standard of care in patients requiring moderate-dose corticosteroids for symptomatic SLE. METHODS: This prospective, randomised, double-blind, phase 4, pilot study (NCT01753401) enrolled 38 patients with persistently active SLE involving skin and/or joints. Enrolled patients received RCI, 40 U daily or 80 U every other day, or volume-matched placebo gel, for 8 weeks, with dose tapering to twice weekly during weeks 5-8...
2016: Lupus Science & Medicine
Agneta Zickert, Vilija Oke, Ioannis Parodis, Elisabet Svenungsson, Yvonne Sundström, Iva Gunnarsson
OBJECTIVES: Interferon (IFN)-α is thought to be central in the pathogenesis for lupus nephritis (LN) and recent studies also indicate a role for IFNλ. Little is known about these cytokines in the context of treatment response. We studied levels of IFNα and IFNλ in patients with LN in association with clinical and histological response (HR) to treatment. METHODS: Fifty-six patients with active LN were included. Renal biopsies were performed at baseline and after immunosuppressive therapy...
2016: Lupus Science & Medicine
Meggan Mackay, Michaela Oswald, Jorge Sanchez-Guerrero, Juan Lichauco, Cynthia Aranow, Sean Kotkin, Ilya Korsunsky, Peter K Gregersen, Betty Diamond
No abstract text is available yet for this article.
2016: Lupus Science & Medicine
Diane Apostolopoulos, Rangi Kandane-Rathnayake, Sudha Raghunath, Alberta Hoi, Mandana Nikpour, Eric F Morand
OBJECTIVES: To determine factors associated with damage accrual in a prospective cohort of patients with SLE. METHODS: Patients with SLE who attended the Lupus Clinic at Monash Health, Australia, between 2007 and 2013 were studied. Clinical variables included disease activity (Systemic Lupus Erythematosus Disease Activity Index-2K, SLEDAI-2K), time-adjusted mean SLEDAI, cumulative glucocorticoid dose and organ damage (Systemic Lupus International Collaborating Clinics Damage Index (SDI))...
2016: Lupus Science & Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"